Keytruda

Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Published: November 29, 2025 Merck & Co., Inc. (NYSE: MRK) heads into the last month of 2025 riding a powerful wave of oncology wins, big‑ticket acquisitions and fresh analyst upgrades that have pushed the stock to new 52‑week highs. As

29 November 2025

Merck (MRK) Stock Today – November 26, 2025: Keytruda Wins, Analyst Upgrades and Big Money Buying Keep Shares Near Record Highs

Merck & Co., Inc. (NYSE: MRK) spent Wednesday trading just below fresh 52‑week highs, as Wall Street continues to digest a powerful mix of positive drug news, upbeat earnings, and a wave of analyst upgrades and institutional buying. Merck stock

26 November 2025

Analyst Ratings · Financial News · Investment · NYSE:MRK · Pharmaceuticals · Stock Market

Merck (MRK) Stock Soars on FDA Keytruda Approval and Wells Fargo Upgrade – 25 November 2025

Merck & Co., Inc. (NYSE: MRK) is back in the market’s spotlight this Tuesday, with the pharmaceutical giant’s shares extending a powerful rally fuelled by fresh regulatory wins and a major Wall Street upgrade. As of early-afternoon trading on 25

25 November 2025

Company Upgrades · FDA Approval · Investment News · NYSE:MRK · Pharmaceuticals · Stock Market

MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

Merck & Co., Inc. (NYSE: MRK) is in rally mode on Monday, November 24, 2025. By early afternoon, MRK stock is trading around $101–$102 per share, up roughly 3.5–3.8% on the day, near its highest levels of 2025 and within

24 November 2025

Analyst Ratings · Company Earnings · Investment News · NYSE:MRK · Pharmaceuticals · Stock Market

Merck Stock Jumps on Wells Fargo Upgrade and New Keytruda Wins – MRK Today, November 24, 2025

Merck & Co., Inc. (NYSE: MRK) is suddenly back in the market’s spotlight. On Monday, 24 November 2025, Merck’s share price surged to around $102, up roughly 4–4.5% on the day, after a bullish analyst upgrade collided with fresh regulatory

24 November 2025

Company Updates · Healthcare Industry · Investment · NYSE:MRK · Pharma News · Stock Market

Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck & Co., Inc. (NYSE: MRK) extended this week’s rally on Wednesday as investors digested fresh late‑stage results for its investigational oral PCSK9 inhibitor and an FDA clearance that supports broader precision use of Keytruda-based therapy. Below is what changed

12 November 2025

Biotech News · Investment Analysis · Medical Research · NYSE:MRK · Pharmaceuticals · Stock Market

Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Rallies on Nov. 11, 2025: FDA Approves New Keytruda Companion Diagnostic; Fresh SITC Combo Data, and Dow Momentum

Published: November 11, 2025 At a glance (today) Market move: MRK helps lead the Dow’s advance By early afternoon Tuesday, Merck & Co. (NYSE: MRK) shares were up about 3.9%, helping lead the Dow Jones Industrial Average higher; Nike and

11 November 2025

Cancer Research · FDA Approvals · Immunotherapy · NYSE:MRK · Pharma News · Stock Market